Staphylococcus aureus acquires resistance to glycopeptide antibiotic vancomycin via CXCL10

Int Immunopharmacol. 2024 May 10:132:111780. doi: 10.1016/j.intimp.2024.111780. Epub 2024 Apr 10.

Abstract

Background: Glycopeptide antibiotic vancomycin is a bactericidal antibiotic available for the infection to Staphylococcus aureus (SA), however, SA has a strong adaptive capacity and thereby acquires resistance to vancomycin. This study aims to illuminate the possible molecular mechanism of vancomycin resistance of SA based on the 16S rRNA sequencing data and microarray profiling data.

Methods: 16S rRNA sequencing data of control samples and urinary tract infection samples were retrieved from the EMBL-EBI (European Molecular Biology Laboratory - European Bioinformatics Institute) database. Correlation of gut flora and clinical indicators was evaluated. The possible targets regulated by SA were predicted by microarray profiling and subjected to KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis. CXCL10 gene knockout and overexpression were introduced to evaluate the effect of CXCL10 on the virulence of SA and the resistance to vancomycin. SA strains were co-cultured with urethral epithelial cells in vitro. The presence of SA virulence factors was detected using PCR. Biofilm formation of SA strains was assessed using the microtiter plate method. Furthermore, the antibiotic sensitivity of SA strains was evaluated through vancomycin testing.

Results: Gut flora and its species abundance had significant difference between urinary tract infection and control samples. SA was significantly differentially expressed in urinary tract infection samples. Resistance of SA to vancomycin mainly linked to the D-alanine metabolism pathway. SA may participate in the occurrence of urinary tract infection by upregulating CXCL10. In addition, CXCL10 mainly affected the SA resistance to vancomycin through the TLR signaling pathway. In vitro experimental results further confirmed that the overexpression of CXCL10 in SA increased SA virulence and decreased its susceptibility to vancomycin. In vitro experimental validation demonstrated that the knockout of CXCL10 in urethral epithelial cells enhanced the sensitivity of Staphylococcus aureus (SA) to vancomycin.

Conclusion: SA upregulates the expression of CXCL10 in urethral epithelial cells, thereby activating the TLR signaling pathway and promoting resistance to glycopeptide antibiotics in SA.

Keywords: 16S rRNA sequencing; Antibiotic resistance; CXCL10; Glycopeptide antibiotic vancomycin; Gut flora; Staphylococcus aureus; TLR signaling pathway; Urinary tract infection.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Biofilms / drug effects
  • Chemokine CXCL10* / genetics
  • Chemokine CXCL10* / metabolism
  • Epithelial Cells / drug effects
  • Epithelial Cells / microbiology
  • Female
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Male
  • RNA, Ribosomal, 16S / genetics
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus* / drug effects
  • Staphylococcus aureus* / genetics
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / microbiology
  • Vancomycin Resistance* / genetics
  • Vancomycin* / pharmacology

Substances

  • Vancomycin
  • Anti-Bacterial Agents
  • Chemokine CXCL10
  • CXCL10 protein, human
  • RNA, Ribosomal, 16S